| Literature DB >> 33288314 |
Wim Van Damme1, Ritwik Dahake2, Remco van de Pas3, Guido Vanham3, Yibeltal Assefa4.
Abstract
The variation in the speed and intensity of SARS-CoV-2 transmission and severity of the resulting COVID-19 disease are still imperfectly understood. We postulate a dose-response relationship in COVID-19, and that "the dose of virus in the initial inoculum" is an important missing link in understanding several incompletely explained observations in COVID-19 as a factor in transmission dynamics and severity of disease. We hypothesize that: (1) Viral dose in inoculum is related to severity of disease, (2) Severity of disease is related to transmission potential, and (3) In certain contexts, chains of severe cases can build up to severe local outbreaks, and large-scale intensive epidemics. Considerable evidence from other infectious diseases substantiates this hypothesis and recent evidence from COVID-19 points in the same direction. We suggest research avenues to validate the hypothesis. If proven, our hypothesis could strengthen the scientific basis for deciding priority containment measures in various contexts in particular the importance of avoiding super-spreading events and the benefits of mass masking.Entities:
Keywords: COVID-19; Initial infectious inoculum; Public health; SARS-CoV-2; Viral dose
Year: 2020 PMID: 33288314 PMCID: PMC7686757 DOI: 10.1016/j.mehy.2020.110431
Source DB: PubMed Journal: Med Hypotheses ISSN: 0306-9877 Impact factor: 1.538
Evidence from various pathogens on the importance of the dose of the initial inoculum.
| Pathogen | Observations |
|---|---|
| Influenza | Viral dose-dependent increase in severity of symptoms in human volunteer challenge studies with different influenza strains Dynamic transmission models suggest that with a small initial dose of the virus, the disease progresses through an asymptomatic course, for an intermediate value, it takes a typical course, and for a large initial dose of the virus, the disease becomes severe Severe disease possibly correlated with higher infectious doses in the 1918–19 influenza “Spanish flu” pandemic The duration of viral shedding of influenza A(H1N1)pdm09 is determined by the severity of the disease Asymptomatic patients or “silent spreaders” may contribute little to the transmission |
| Coronaviruses | For SARS, higher nasopharyngeal viral load correlated with proximity to the index patient High nasopharyngeal viral loads correlated with disease severity, poorer outcomes, and mortality also seen in MERS A dose-response relationship of Human Coronavirus 229E (HCoV-229E) with severity of infection in human volunteer challenge studies |
| Human Immunodeficiency Virus (HIV) | The probability of getting infected varies according to the routes of transmission (with highest risk from blood transfusion) and depends significantly on the infectious dose High volume of the viral inoculum leads to shorter incubation periods and faster disease progression The relation between viral load in the blood (cut-off 1500 copies/mL) and the chances of heterosexual transmission has been repeatedly and convincingly shown in studies with discordant couples |
| Measles | Higher initial doses associated with more severe disease and higher mortality in secondary (multiple) cases that arise from index cases within the house environment than single cases that arise from an index case outside the house Secondary cases infected through a severe case have higher mortality and these severe cases have shorter incubation periods |
| Tuberculosis (TB) | More secondary infections from TB-infected persons who are sputum smear-positive than from persons who are culture-positive only Higher doses of infectious particles are more likely to result in tuberculosis Dose-dependent infectivity in studies using ultra-low doses of Evidence from TB in patients from the US point in the same direction |
The development of bacterial pneumonia more likely when the dose of the inoculum exceeds a threshold of host immune response and antibacterial protection. A relationship between the dose and the development of pneumonia in animal models | |
SARS: Severe Acute Respiratory Syndrome, MERS: Middle East Respiratory Syndrome, US: United States.
Key observations of immune responses against SARS-CoV-2 in mild and severe COVID-19.
| Immune response | Key observations in COVID-19 |
|---|---|
| Cytokines/chemokines | Increased plasma levels of pro-inflammatory cytokines and chemokines (especially IL-2, IL-6, IL-10, and TNFɑ in severe cases) compared to mild cases or healthy controls. The host pro-inflammatory response hypothetically induces an immune pathology resulting in uncontrolled dysregulation of the immune system. Rapid course of ALI and ARDS occurring in severe disease including massive cytokine and chemokine release, the so-called “cytokine storm”. An increase in serum cytokine/chemokine levels and neutrophil-lymphocyte-ratio (NLR) correlated with the severity of COVID-19, implicating hyper-inflammatory responses in pathogenesis and adverse outcomes. |
| Interferon (IFN) type I/III | Patients with severe COVID-19 demonstrate remarkably impaired IFN-I activation as compared to mild or moderate cases. Lack of robust IFN-I/III signatures from infected cell lines, primary bronchial cells, and a ferret model. |
| T cells, B cells, and NK cells | Lymphocytopaenia and modulation in lymphocyte balance associated with a decrease in levels of circulating CD4+ cells, CD8+ cells, B cells, and NK cells; and a decrease in monocytes, eosinophils, basophils, and total neutrophils have been commonly observed to be directly correlated with disease severity and death. Upon entry, SARS-CoV-2 viral peptides enable the development of virus-specific effector and memory T cells, and patients with mild disease present with normal or slightly higher T and NK cell counts. The cause of peripheral T cell loss in moderate to severe COVID-19 is unclear. Direct infection of T cells has not been reported (which occurs in MERS-CoV infections) Lymphocyte responses postulated to be influenced by the dose of the virus. |
| Antibodies | SARS-CoV-2 infection also involves T and B cell immunity and anti-viral neutralizing antibody responses; delayed in severe patients. IgM primary antibody response observed within the first week following symptoms while IgG antibodies follow and are assumed to retain a life-long immunity. High serum antibody levels have been associated with more severe disease. |
| Apoptosis | CTL responses lyse virus-infected tissue cells in mild patients. It has also been proposed that apoptosis of lymphocytes induces lymphocytopaenia in critically ill patients. |
IL: Interleukin, IFN: Interferon, TNFɑ: Tumour Necrosis Factor (alpha), ICU: Intensive Care Unit, ALI: Acute Lung Injury, ARDS: Acute Respiratory Distress Syndrome, NK: Natural Killer, CTL: Cytotoxic T-Lymphocyte.
Key differences between immune responses to mild and severe COVID-19.
| Immune response | Mild COVID-19 | Severe COVID-19 |
|---|---|---|
| Cytokines/chemokines | Elevated cytokines/chemokines but limited pro-inflammatory responses | Highly elevated cytokines/chemokines with more pro-inflammatory responses eventually leading to “cytokine storms” |
| Interferon (IFN) type I/III | Possible activation of IFN pathway | Delayed or blocked activation of IFN pathway |
| T cells, B cells, and NK cells | Normal or slightly increased T cells (no lymphocytopaenia) | Decreased T cells, NK cells, and eosinophils (lymphocytopaenia and eosinopaenia) |
| Neutralizing antibodies | Anti-viral neutralizing antibody response | Inefficient T&B cell response (exhaustion) and delayed neutralizing antibody response |
| Apoptosis | Early apoptosis of virus-infected cells by CTL (CD8+) and NK cells causing viral clearance | Delayed apoptosis of CTL (CD8+) and NK cells |
IFN: Interferon, CTL: Cytotoxic T-Lymphocyte, NK: Natural Killer.
Fig. 1The role of the dose of the initial viral inoculum on the immune system leading to mild/severe disease (based on immune responses observed in mild versus severe COVID-19) [Adapted from Ref. [42]]. Top panel: Low dose of the SARS-CoV-2 initial inoculum elicits an early innate immune response (INF pathway; elevated cytokines/chemokines; limited pro-inflammatory response) and normal adaptive/cellular response leading to early clearance of the virus with a limited spectrum of COVID-19 and mild disease. Bottom panel: High dose of the SARS-CoV-2 initial inoculum delays or blocks innate immune response (limited INF pathway; highly elevated cytokines/chemokines; elevated pro-inflammatory response leading to “cytokine storms”) and decreased or exhausted adaptive/cellular response leading to viral evasion of the immune system with increased spectrum of COVID-19 and severe disease.
Some incompletely explained observations in the SARS-CoV-2 transmission and COVID-19 disease that may be explained by the hypothesis.
| Incompletely explained observations | Possible explanation through the hypothesis |
|---|---|
| Super-spreading events: Intensive transmission in crowded environments, especially indoor events in poorly ventilated environments | These conditions are favourable for transmission of higher doses of initial infectious inocula, due to intensive exposure over a longer time. |
| Clusters of severe cases and clusters of mild cases | Primary cases with severe disease result in transmitting higher doses of infectious inocula, while those with mild disease transmit lower doses. |
| Health care workers with a low-risk profile got severe COVID-19, infected from very sick patients, e.g. during intubation | Proximity to patients with severe disease enables being infected with higher doses of infectious inoculum. |
| Severe epidemics mostly in dense urban centres. | Primary cases in dense urban centres result in transmission of higher doses of infectious inocula, due to greater proximity and longer duration of exposure, leading to more severe disease in secondary cases. |
| Less explosive epidemics in countries outside 30°–60° Northern latitude. In sub-Saharan Africa and South and Southeast Asia, the virus spread with a less steep exponential pattern than in Western Europe or the United States. | Colder climates may be more conducive for transmission of higher doses of the virus, as people live mostly indoors. In warmer and humid climates, where people are mostly outdoors, the aerosols may diffuse more rapidly and lead to lower doses of the virus being transmitted. |
| Many people remain asymptomatic or pauci-symptomatic | Individuals infected with lower doses of infectious inocula possibly remain asymptomatic or develop milder disease due to their immune systems being able to mount a more robust response against a smaller dose of the virus. |